Market	Type	Industry	Raised	Date
AIM	Early stage	Pharmaceuticals & Biotech	£5.0m	Dec 2006

CONTACTS

CEO: Andrew Lynn 01223-763 760

ADVISERS

Oxford Capital Partners
David Mott 01865-860760	201 Cumnor Hill Oxford OX2 9PJ

Sloane Robinson Private Equity
020-7929 2771	20 Saint Dunstans Hill London

COMMENT

Biotechnology company.

Related Articles

• Funding round for OGeS
• OrthoMimetics secures £5 million
• OrthoMimetics in £5 million funding
• Technology company powers up
• Helveta ready for next level

People who read this article also read ...

• Sagicor buys BSU
• BioControl secures £500,000
• Cruise operator joins AIM
• 3i increases AES stake